Enzyme replacement therapy: Conception, chaos and culmination

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 358, Issue 1433, 2003, Pages 915-919

  Brady, Roscoe O ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Benefits to patients; Enzyme replacement; Lipid storage disorders

Indexed keywords

ENZYME;

EID: 0038777081     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2003.1269     Document Type: Conference Paper

References (45)

1. Aghion, H. 1934 La maladie de Gaucher dans l'enfance. PhD thesis, Paris University, France.
2. Amalfitano, A. (and 17 others) 2001 Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 3, 132-138.
3. Ashwell, G. & Morell, A. 1974 The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol. 41, 99-128.
4. Barton, N. W., Furbish, F. S., Murray, G. J., Garfield, M. & Brady, R. O. 1990 Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl Acad. Sci. USA 87, 1913-1916.
5. Barton, N. W. (and 11 others) 1991 Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. New Eng. J. Med. 324, 1464-1470.
6. Brady, R. O. 1966 Sphingolipidoses. New Eng. J. Med. 275, 312-318.
7. Brady, R. O. 1978 Sphingolipidoses. A. Rev. Biochem. 47, 687-713.
8. Brady, R. O. & Furbish, F. S. 1982 Enzyme replacement therapy: specific targeting of exogenous enzymes to storage cells. In Membranes and transport, vol. 2 (ed. A. N. Martonosi), pp. 587-592. New York: Plenum.
9. Brady, R. O., Kanfer, J. & Shapiro, D. 1965a Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J. Biol. Chem. 240, 39-42.
10. Brady, R. O., Kanfer, J. N. & Shapiro, D. 1965b Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem. Biophys. Res. Commun. 18, 221-225.
11. Brady, R. O., Kanfer, J. N., Bradley, R. M. & Shapiro, D. 1966a Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 45, 1112-1115.
12. Brady, R. O., Kanfer, J. N., Mock, M. B. & Fredrickson, D. S. 1966b The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc. Natl Acad. Sci. USA 55, 366-369.
13. Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L. & Laster, L. 1967 Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. New Eng. J. Med. 276, 1163-1167.
14. Brady, R. O., Johnson, W. G. & Uhlendorf, B. W. 1971a Identification of heterozygous carriers of lipid storage diseases. Am. J. Med. 51, 423-431.
15. Brady, R. O., Uhlendorf, B. W. & Jacobson, C. B. 1971b Fabry's disease: antenatal detection. Science 172, 174-175.
16. Brady, R. O., Tallman, J. F., Johnson, W. G., Gal, A. E., Leahy, W. E., Quirk, J. M. & Dekaban, A. S. 1973 Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry's disease. New Eng. J. Med. 289, 9-14.
17. Brady, R. O., Pentchev, P. G., Gal, A. E., Hibbert, S. R. & Dekaban, A. S. 1974 Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher's disease. New Eng. J. Med. 291, 989-993.
18. Dale, G. L., Villacorte, D. & Beutler, E. 1976 Solubilization of glucocerebrosidase from human placenta and demonstration of a phospholipid requirement for its catalytic activity. Biochem. Biophys. Res. Commun. 71, 1048-1053.
19. de Duve, C. 1964 From cytases to lysosomes. Fed. Proc. 23, 1045-1049.
20. Doebber, T. W., Wu, M. S., Bugianesi, R. L., Ponpipom, M. M., Furbish, F. S., Barranger, J. A., Brady, R. O. & Shen, T. Y. 1982 Enhanced macrophage uptake of synthetically glycosylated human placental β-glucocerebrosidase. J. Biol. Chem. 257, 2193-2199.
21. Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E. & Desnick, R. J. 2001 Safety and efficacy of recombinant human alpha-galactosidase A: replacement therapy in Fabry's disease. New Eng. J. Med. 345, 9-16.
22. Furbish, F. S., Blair, H. E., Shiloach, J., Pentchev, P. G. & Brady, R. O. 1977 Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration. Proc. Natl Acad. Sci. USA 74, 3560-3563.
23. Furbish, F. S., Steer, C. J., Krett, N. L. & Barranger, J. A. 1981 Lysosomal hydrolases as glycoproteins. Biochim. Biophys. Acta 673, 425-434.
24. Goldstone, A. & Koenig, H. 1970 Lysosomal hydrolases as glycoproteins. Life Sci. 9, 1341-1350.
25. Grabowski, G. A., Barton, N. W., Pastores, G., Dambrosia, J. M., Banerjee, T. K., McKee, M. A., Parker, C., Schiffmann, R., Hill, S. C. & Brady, R. O. 1995 Enzyme therapy in Gaucher disease type 1: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Int. Med. 122, 33-39.
26. Johnson, W. G. & Brady, R. O. 1972 Ceramidetrihexosidase from human placenta. Methods Enzymol. 28, 849-856.
27. Johnson, W. G., Desnick, R. J., Long, D. M., Sharp, H. L., Krivit, W., Brady, B. & Brady, R. O. 1973 Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. Birth Defects Original Article Ser. 9, 120-124.
28. Kakkis, E. D. (and 11 others) 2001 Enzyme-replacement therapy in mucopolysaccharidosis I. New Eng. J. Med. 344, 182-188.
29. Kampine, J. P., Brady, R. O., Kanfer, J. N., Feld, M. & Shapiro, D. 1967 The diagnosis of Gaucher's disease and Niemann-Pick disease using small samples of venous blood. Science 155, 86-88.
30. Klenk, E. 1934 Uber die Natur der Phosphatide der Milz bei Niemann-Pickschen Kronkheit. Z. Physiol. Chem. 229, 151-156.
31. Kolodny, E. H., Brady, R. O. & Volk, B. W. 1969 Demonstration of an alteration of ganglioside metabolism in Tay-Sachs disease. Biochem. Biophys. Res. Commun. 37, 526-531.
32. Pentchev, P. G., Brady, R. O., Hibbert, S. R., Gal, A. E. & Shapiro, D. 1973 Isolation and characterization of glucocerebrosidase from human placental tissue. J. Biol. Chem. 248, 5256-5261.
33. Pentchev, P. G., Brady, R. O., Gal, A. E. & Hibbert, S. R. 1975 Replacement therapy for inherited enzyme deficiency: sustained clearance of accumulated glucocerebroside in Gaucher's disease following infusion of purified glucocerebrosidase. J. Mol. Med. 1, 73-78.
34. Raz, A., Bucana, C., Fogler, W. E., Poste, G. & Fidler, I. J. 1981 Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res. 41, 487-494.
35. Schiffmann, R. (and 16 others) 2000 Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl Acad. Sci. USA 97, 365-370.
36. Schiffmann, R., Kopp, J. B., Austin, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E. & Brady, R. O. 2001a Enzyme replacement therapy in Fabry disease. A randomized controlled trial. JAMA 285, 2743-2749.
37. Schiffmann, R., Kopp, J. B., Moore, D. F., Weibel, T., Charia, G. & Brady, R. O. 2001b Efficacy and safety of prolonged enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 69(Suppl.), 222.
38. Stahl, P. D., Rodman, J. S., Miller, M. J. & Schlesinger, P. H. 1978 Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc. Natl Acad. Sci. USA 75, 1599-1603.
39. Svennerholm, L. 1962 The chemical structure of normal human brain and Tay-Sachs gangliosides. Biochem. Biophys. Res. Commun. 9, 436-441.
40. Sweeley, C. C. & Klionsky, B. 1963 Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J. Biol. Chem. 238, 3148-3150.
41. Tallman, J. F., Johnson, W. G. & Brady, R. O. 1972 The metabolism of Tay-Sachs ganglioside: catabolic studies with lysosomal enzymes from normal and Tay-Sachs brain tissue. J. Clin. Invest. 51, 2339-2345.
42. Trams, E. G. & Brady, R. O. 1960 Cerebroside synthesis in Gaucher's disease. J. Clin. Invest. 39, 1546-1550.
43. Weinreb, N. J., Brady, R. O. & Tappel, A. L. 1968 The lysosomal localization of sphingolipid hydrolases. Biochim. Biophys. Acta 159, 141-146.
44. Weinreb, N. J. (and 10 others) 2002 Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med. 113, 112-119.
45. Zirzow, G. C., Sanchez, O. A., Murray, G. J., Brady, R. O. & Oldfield, E. H. 1999 Delivery, distribution and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain. Neurochem. Res. 24, 301-305.